558. Deputy Aengus Ó Snodaigh asked the Minister for Health if consideration will be given to requesting the National Centre for Pharmacoeconomics to re-evaluate its decision in 2013 not to recommend a full pharmacoeconomic evaluation and its decision in 2017 that reimbursement is not recommended at the submitted price, given that the price in two years may have substantially dropped since then, the number of patients in Ireland is low and Plenadren has a variety of prices in other EU states. [44300/20]

Summary

558. Deputy Aengus Ó Snodaigh asked the Minister for Health if consideration will be given to requesting the National Centre for Pharmacoeconomics to re-evaluate its decision in 2013 not to recommend a full pharmacoeconomic evaluation and its decision in 2017 that reimbursement is not recommended at the submitted price, given that the price in two years may have substantially dropped since then, the number of patients in Ireland is low and Plenadren has a variety of prices in other EU states. [44300/20]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Pharmaceutical Sector

  xml · EN · 17 December 2020

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.